动物造模,前列腺癌人源性异种移植 zi-bio 2024-03-22 931

　　Objective: To establish a human derived xenograft model for prostate cancer and evaluate the anti-tumor effects of different treatment regimens

　　Method: Fresh human prostate cancer surgical specimens were mixed with matrix gel and transplanted subcutaneously into nude mice supplemented with exogenous androgens. The tumor growth was continuously monitored, its fidelity was evaluated, and it was continuously passaged; Divide tumor bearing mice into four groups: docetaxel group, castration group, docetaxel combined castration group, and control group. During treatment, measure tumor volume and mouse weight changes. After treatment, measure the concentration of total prostate specific antigen (tPSA) in serum and histopathological changes to evaluate the treatment effect

　　Result: A PDX model of prostate cancer was successfully established, including hormone sensitive (D17225) and castration resistant (C40019) tumors. Pathological analysis showed that the transplanted tumor well preserved the main characteristics of the patient's primary tumor; Pathological histology and serum tPSA testing showed that the docetaxel group and the docetaxel combined with castration group showed good therapeutic effects in the D17225 model, and the latter had a more significant anti-tumor effect

　　Conclusion: A prostate cancer PDX model has been successfully established and stably passaged. Docetaxel monotherapy or combined castration treatment has significant therapeutic effects on hormone sensitive (D17225) prostate cancer PDX models